Clinical trials: Intra-arterial Thrombolysis
Stroke, Acute Ischemic
Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke
Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days.
- Trial name
- IA-SUCCESS (NCT06768138)
- Testing
- Intra-arterial infusion of Alteplase
- Where
- France
- Volunteers
- 626 people
- Sponsor
- Central Hospital, Nancy, France
Ischemic Stroke
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and…
- Trial name
- EXTEND-IA (NCT01492725)
- Testing
- Intra-arterial Clot Retrieval with Solitaire device, intravenous tissue plasminogen activator (tPA)
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 70 people
- Sponsor
- Neuroscience Trials Australia
Cerebral Stroke, Cerebrovascular Accident
Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke
THRACE is a controled, multicenter and randomized trial. The primary objective of this study is to determine whether a combined approach intravenous thrombolysis (IV) + Mechanical thrombectomy is superior to the reference…
- Trial name
- THRACE (NCT01062698)
- Testing
- Alteplase (rt-PA)/Actilyse, Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)
- Where
- France
- Volunteers
- 412 people
- Sponsor
- Central Hospital, Nancy, France
Stroke, Cerebrovascular Accident
Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS)
The purpose of this study is to determine whether intra-arterial rt-PA within 6 hours from an ischemic stroke onset, compared with intravenous infusion of the same drug within 3 hours, increases the proportion of independent…
- Trial name
- NCT00540527
- Testing
- local interarterial recombinant tissue plasminogen activator, intravenous (IV) rt-PA
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Niguarda Hospital
Acute Ischemic Stroke
OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion
PEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of primary intra-arterial thrombolysis in…
- Trial name
- PEARL-MeVO (NCT07137832)
- Testing
- Primary intra-arterial thrombolysis, Standard medical treatment
- Where
- China
- Volunteers
- 530 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stroke, Acute Ischemic, Endovascular Thrombectomy
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT.
- Conditions
- Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
- Trial name
- ACT-REACT (NCT07687056)
- Testing
- Tenecteplase or Alteplase- depending upon availability at each treating centre, Control
- Where
- 13 sites in Australia, Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
- Trial name
- NCT00499902
- Testing
- alfimeprase
- Where
- 22 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- ARCA Biopharma, Inc.
Ischemic Stroke, Acute Disease
Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial
The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation…
- Trial name
- ALLY II TNK (NCT06949228)
- Testing
- tenecteplase
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- ProMedica Health System
Stroke, Cerebrovascular Disorders
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit…
- Conditions
- Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
- Trial name
- RESCUE MeVO (NCT07185022)
- Testing
- Intra-arterial Thrombolysis, Best Medical Treatment
- Where
- 6 sites in China
- Volunteers
- 282 people
- Sponsor
- The Second Hospital of Anhui Medical University
Stroke, Acute Ischemic, Large Vessel Occlusion
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy
The NEWLINE trial is a multicenter, randomized, open-label, blinded endpoint (PROBE) trial evaluating whether adjunctive low-dose intra-arterial alteplase administered immediately after successful endovascular thrombectomy…
- Conditions
- Stroke, Acute Ischemic, Large Vessel Occlusion, Thrombectomy
- Trial name
- NEWLINE (NCT07727395)
- Testing
- Alteplase, Endovascular thrombectomy
- Where
- 11 sites in Vietnam
- Volunteers
- 416 people
- Sponsor
- 115 People's Hospital
Medium Vessel Occlusion, Ischemic Stroke, Acute
Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion
A multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) phase III trial is planned to evaluate the efficacy and safety of intra-arterial thrombolysis (IAT) in patients with acute ischemic stroke caused by…
- Trial name
- IAT-MEVO (NCT07668323)
- Testing
- Recombinant Tissue Plasminogen Activator (rt-PA), Intra-arterial Thrombolysis, Best Medical Management
- Where
- China
- Volunteers
- 372 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ischemic Stroke, Acute
Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization
The goal of this clinical trial is to evaluate whether intra-arterial (IA) rhTNK-tPA thrombolysis can improve neurological outcomes in acute large vessel occlusion patients after successful mechanical thrombectomy (MT)…
- Trial name
- ANGEL-TNK (NCT05624190)
- Testing
- Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA), Best Medical Management
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke From Large Vessel Occlusion
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy
This is a prospective, single-arm, open-label study to evaluate the efficacy of intra-arterial tenecteplase in improving microvascular reperfusion following successful large vessel recanalization.
- Trial name
- INTIMA-MT (NCT06904911)
- Testing
- intra-arterial tenecteplase administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Stroke, Cerebrovascular Accident
Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke
SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with recombinant tissue-plasminogen activator (rt-PA) and/or…
- Trial name
- SYNTHESIS EXP (NCT00640367)
- Testing
- Alteplase IA and/or mechanical thrombolysis, Alteplase IV
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Niguarda Hospital
Stroke
Interventional Management of Stroke (IMS) III Trial
The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.
- Trial name
- IMSIII (NCT00359424)
- Testing
- IV rt-PA alone, endovascular therapy
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 656 people
- Sponsor
- Joseph Broderick
Central Retinal Artery Occlusion, Visual Field
Changes of Visual Field Defects After IAT for CRAO
Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis.
- Conditions
- Central Retinal Artery Occlusion, Visual Field, Intra-arterial Thrombolysis
- Trial name
- NCT05739487
- Testing
- selective intra-arterial thrombolysis
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Arterial Ischemic Stroke
National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke
The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients
- Trial name
- KID-CLOT (NCT03887143)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris